( Poster Number: U4 ...)Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting,Health

Poster Number: U4 MORAb-003 A Phase I Study of MORAb-003, a Fully June 2, 2007 Abstract No: Humanized Monoclonal Antibody against 2:00 PM - 6:00 PM 5553 Folate Receptor Alpha, in Advanced Location: S Hall A2 Epithelial Ovarian Cancer Poster Number: R7 E7974 A Phase I Trial of E7974 Administered June 3, 2007 Abstract No: on Days 1 and 15 of a 28-Day Cycle in 8:00 AM - 12:00 PM 2550 Patients With Solid Malignancies Location: S Hall A2 Poster Number: B6 E7974 A Phase I Trial of E7974 Administered June 3, 2007 Abstract No: on Days 1, 8, and 15 of a 28-Day Cycle 8:00 AM - 12:00 PM 2543 in Patients With Solid Malignancies Location: S Hall A2 Poster Number: A13

The expansion of Eisai's oncology discovery, research and clinical development capabilities complements the company's establishment of its oncology sales and marketing operations in the United States. Through its acquisition in 2006 of four marketed oncology products, Eisai also obtained key oncology personnel and expertise, including a sales force. Most recently, Eisai acquired Morphotek, Inc., which discovers and develops therapeutic monoclonal antibodies through its proprietary technologies. Morphotek has preclinical and clinical development programs underway in several therapeutic categories, including oncology. Both acquisitions expand Eisai's capabilities into the biologic therapeutics field.

Eisai is committed to building its commercial oncology infrastructure and is well positioned to market new oncology products that originate from its research and discovery efforts or through future acquisition, co-promotion or in-licensing opportunities. That growth will help Eisai address the unmet medical needs of patient
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference